Westfield Capital Management
ADPT icon

Westfield Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Westfield Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.5M Sell
4,267,645
-1,169,073
-22% -$17.9M 0.3% 97
2026
Q1 		$75.5M Buy
5,436,718
+1,376,237
+34% +$21.9M 0.32% 105
2025
Q4 		$65.9M Buy
+4,060,481
New +$66.3M 0.27% 125

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Westfield Capital Management's ADPT Position: Q2 2026 in Review

Westfield Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 22% in Q2 2026, selling an estimated $17.9M and leaving 4,267,645 shares worth $91.5M. The position accounts for 0.3% of the portfolio, ranked #97.

Westfield Capital Management first reported a position in ADPT in Q4 2025 and has held it in 3 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Westfield Capital Management held 4,267,645 shares of Adaptive Biotechnologies worth $91.5M as of Q2 2026.
  • Westfield Capital Management sold 1,169,073 Adaptive Biotechnologies shares in Q2 2026, an estimated $17.9M.
  • Adaptive Biotechnologies made up 0.3% of Westfield Capital Management's portfolio in Q2 2026, its #97 holding.
  • Westfield Capital Management first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 3 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.